OrbiMed

About

Portfolio · 37

Biobeat

24 Hour Cuff-less Blood Pressure Monitoring

1 round $50.0M committed Latest: 2026-01

InspireMD

Stent System Technology for Preventing Embolization

Led ★ 2 rounds $171.6M committed Latest: 2025-08

Chemomab Therapeutics

Innovative Treatments for Patients with Fibro-Inflammatory-Related Diseases

5 rounds $90.5M committed Latest: 2024-07

Averna Therapeutics

Genomic Medicines that Insert Therapeutic Genes into Safe Harbors Within the DNA

1 round $82.0M committed Latest: 2024-06

Fore Biotherapeutics

Precision Oncology Treatments

3 rounds $144.5M committed Latest: 2023-08

BiomX

Microbiome Therapies for Chronic Diseases

4 rounds $113.5M committed Latest: 2023-02

DarioHealth

Digital Therapeutics for Treating Chronic Conditions

1 round $50.0M committed Latest: 2022-06

MDClone

Healthcare Data Analytics Platform

4 rounds $104.3M committed Latest: 2022-03

Nucleix

Noninvasive Testing for Early Detection of Cancer

3 rounds $82.4M committed Latest: 2022-01

ImmPACT Bio

CAR-T Cell Therapies for Treating Cancer

3 rounds $129.0M committed Latest: 2022-01

SpliSense

Developing transformative RNA-based treatments for unmet needs relating to diverse pulmonary diseases.

Led ★ 1 round $28.5M committed Latest: 2021-05

MobileODT

AI-based Cervical Cancer Screening Solutions

Led ★ 2 rounds $16.0M committed Latest: 2020-08

Emendo Biotherapeutics

DNA Correction and Genome-editing Platforms

1 round $61.0M committed Latest: 2020-01

Protekt Therapeutics

PKR Inhibition for Treating Neurodegenerative Diseases

3 rounds $10.3M committed Latest: 2019-11

VYNE Therapeutics

Therapies for the Treatment of Immuno-inflammatory Conditions

2 rounds $80.0M committed Latest: 2019-07

89bio

Treatment for Liver and Metabolic Disorders

1 round $60.0M committed Latest: 2018-10

Bsense Bio Therapeutics

Neuropathic Pain Treatment

1 round $2.7M committed Latest: 2018-09

Ramino-Bio

Oral drug for treating cardio-metabolic disease and rare MSUD

1 round Latest: 2018-09

SmartZyme Biopharma

Improving Enzymes for Glucose Monitoring

2 rounds $4.0M committed Latest: 2018-03

TytoCare

Remote Primary Care and a Home Smart Clinic

2 rounds $32.0M committed Latest: 2018-01

Atox Bio

Immunomodulators for Treatment of Infectious and Inflammatory Diseases

2 rounds $53.0M committed Latest: 2017-12

FUSMobile

Focused Ultrasound Therapy for Chronic Pain

1 round Latest: 2017-07

Mitoconix Bio

Therapeutics for Neurodegenerative Diseases

1 round $20.0M committed Latest: 2017-06

Tisbury Pharmaceuticals

Open-angle Glaucoma Treatment

1 round $32.0M committed Latest: 2017-06

LogicBio Therapeutics

Gene Therapy for Genetic and Infectious Diseases

2 rounds $49.0M committed Latest: 2017-06

SteadyMed Therapeutics

Device for Ongoing Delivery of Injectable Drugs

2 rounds $62.0M committed Latest: 2017-04

Pi Therapeutics

Inhibitors for Cancer Treatment

1 round Latest: 2017-01

Nutrinia

Neonatal Gastrointestinal Treatment

2 rounds $42.0M committed Latest: 2016-08

Ornim Medical

Noninvasive Cerebral Blood Flow Monitoring

3 rounds $50.0M committed Latest: 2016-08

Otic Pharma

Foam-based Products for the Treatment of Ear, Nose, and Throat Disorders

2 rounds $4.3M committed Latest: 2015-05

Xylo Technologies

Minimally Invasive Endosurgical and Imaging Tools

1 round $11.1M committed Latest: 2014-06

Keystone Heart

Embolic Cerebral Protection Devices

1 round $14.0M committed Latest: 2014-05

Treato

Analysis of Prescription Drug Reviews

1 round $14.5M committed Latest: 2013-04

BiolineRx

Oncology Therapeutic Pharmaceutical Candidates

1 round $8.0M committed Latest: 2013-02

RedHill Biopharma

Proprietary Drugs for Gastrointestinal and Infectious Diseases

1 round $6.5M committed Latest: 2012-12

cCAM Biotherapeutics

Monoclonal Antibodies for Cancer Treatment

1 round $8.0M committed Latest: 2012-09

Foxcom

RF-over-fiber Solutions

1 round $4.3M committed Latest: 1999-03

Investment activity

9 portfolio exits on record.

Funds · 8

• OrbiMed Royalty & Credit Opportunities IV — $1.43B Oct 2023
• OrbiMed Private Investments IX — $1.43B Oct 2023
• OrbiMed Asia Partners V — $1.43B Oct 2023
• Fund — $800M Mar 2021
• Fund — $1.2B Mar 2021
• Fund — $1.5B Mar 2021
• 2 — $307M Jan 2016
• 1 — $122M Jan 2010

Q&A

What is OrbiMed's primary investment focus?

OrbiMed is a dedicated healthcare investment firm, focusing on the global healthcare industry, including biopharmaceuticals, medical devices, diagnostics, and healthcare services.

What was OrbiMed's most recent exit?

OrbiMed had an exit in October 2024 with the acquisition of ImmPACT Bio by Lyell Immunopharma.

What is OrbiMed's most recent fund close?

In October 2023, OrbiMed closed three funds, OrbiMed Royalty & Credit Opportunities IV, OrbiMed Private Investments IX, and OrbiMed Asia Partners V, each raising $1.43 billion.

Which portfolio company did OrbiMed exit via a reverse merger in March 2021?

OrbiMed exited Chemomab Therapeutics in March 2021 through a reverse merger with Anchiano Therapeutics, which was listed on NASDAQ.

Can you name a notable public exit for OrbiMed in 2019?

In November 2019, OrbiMed had a public exit with 89bio through a POEvent, raising $85 million on NASDAQ.

What is an example of OrbiMed's recent portfolio company investments?

OrbiMed has invested in companies such as Upstream Bio, which raised $400 million in a Series B round, and Averna Therapeutics, which raised $82 million in a Series A round.

What is the typical investment stage for OrbiMed?

OrbiMed invests across various stages, including Seed, A Round, B Round, C Round, D Round, E Round, F Round, and G Round.

Where is OrbiMed headquartered and where does it have other offices?

OrbiMed is headquartered in New York, with additional offices in San Francisco, Mumbai, Hong Kong, and Shanghai.